One Liberty Properties Reports Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

– Leased over 1.1 Million Square Feet in 2022 – – Occupancy At 99.8% – GREAT NECK, N.Y., March 13, 2023 (GLOBE NEWSWIRE) — One Liberty Properties, Inc. (NYSE: OLP), a real estate investment trust focused on net leased properties, today announced operating results for the quarter and year ended December 31, 2022. “We are excited that we delivered per share net income and AFFO growth as we continue our efforts to produce increasing value over time,” commented Patrick J. Callan, Jr., One Liberty Properties President and Chief Executive. “Revenues and AFFO grew in the fourth quarter and all of 2022, as we effectively navigated the challenging economic backdrop of rising inflation coupled with volatility in interest rates and financial markets. We expect to maintain our disciplined underwriting approach as we seek to acquire and dispose...

Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

Engaging with more than two-thirds of key optometrists and/or ophthalmologists, and top payers on Demodex blepharitis in anticipation of TP-03 August 25, 2023 PDUFA Completed enrollment of Ersa, a Phase 2a trial evaluating TP-03 for MGD with topline data expected in 2H 2023 and initiated Galatea Phase 2a trial evaluating TP-04 for Rosacea Cash runway anticipated into at least 2H 2026 to support planned TP-03 commercialization and continued pipeline development IRVINE, Calif., March 13, 2023 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the full-year ended December 31, 2022, and recent business achievements. “In 2022 we had a...

Getty Images Reports Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) — Getty Images Holdings, Inc. (“Getty Images”) (NYSE: GETY), a preeminent global visual content creator and marketplace, today reported financial results for the fourth quarter and full year ended December 31, 2022. Craig Peters, Chief Executive Officer of Getty Images said, “Today marks Getty Images’ 28th anniversary. Over those 28 years, Getty Images has focused on producing and providing high quality, exclusive and authentic content that is born from our unique expertise, creativity and partnerships. This continues to be the heart of our business and focus. While we continue to see macroeconomic headwinds and foreign exchange impacts, Getty Images produced solid operational performance over 2022 and the fourth quarter. In spite of FX pressures, which impacted our reported revenue, we...

Oportun Reports Fourth Quarter and Full Year 2022

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

4Q22 Aggregate Originations of $610 million, bringing FY22 to $2.9 billion, up 27% 4Q22 Total revenue of $262 million, bringing FY22 to $953 million, up 52% 2023 cost actions enacted to save $48 to 53 million in annualized expenses SAN CARLOS, Calif., March 13, 2023 (GLOBE NEWSWIRE) — Oportun Financial Corporation (Nasdaq: OPRT) (“Oportun”, or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2022. “The fourth quarter exemplified the resilience of Oportun and our business model amidst a difficult macroeconomic backdrop. I’m pleased that we delivered a profitable quarter on an adjusted basis, despite the rising rate environment and the impact of inflation,” said Raul Vazquez, CEO of Oportun. “We grew our average daily principal balance sequentially...

GitLab Reports Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

Quarterly revenue of $122.9 million, up 58% year-over-year Fiscal Fourth Quarter Highlights: Total revenue of $122.9 million GAAP operating margin of (38)%; Non-GAAP operating margin of (11)% GAAP net loss per share of $(0.26); Non-GAAP net loss per share of $(0.03) Fiscal Year 2023 Highlights: Total revenue of $424.3 million GAAP operating margin of (50)%; Non-GAAP operating margin of (21)% GAAP net loss per share of $(1.16); Non-GAAP net loss per share of $(0.46) SAN FRANCISCO, March 13, 2023 (GLOBE NEWSWIRE) — All-Remote – GitLab Inc. (NASDAQ: GTLB), The DevSecOps Platform, today reported financial results for its fourth quarter and full fiscal year of 2023, ended January 31, 2023. “Now more than ever, it is critical for companies to show an immediate return on their software investments,” said Sid Sijbrandij, co-founder...

Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2023, and Recent Developments

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

— Recorded Third Quarter Revenue of $38.0 Million, a 21% Increase Compared to Prior Year Quarter — — Signed $67 Million in Net New Business Orders Resulting in a Backlog of $176 million, an Increase of 26% Year-Over-Year — — Mammalian Cell Manufacturing is Now Online and Process Development Facility Expansions to be Online by End of Calendar Q1 2023, Adding Approximately $120 Million of Revenue Capacity — — Cell and Gene Therapy Facility Expansion Expected to be Online by End of Calendar Q3 2023 — — Reaffirming FY 2023 Revenue Guidance of Between $145 Million and $150 Million — TUSTIN, Calif., March 13, 2023 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...

Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

Pivotal NAVAL-1 study of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open at 70 sites globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 expected in the first half of 2023 Completed initial enrollment into the fourth dose level in the dose escalation part of the Phase 1b/2 trial of Nana-val in advanced EBV+ solid tumors Data from the complete dose escalation part of the Phase 1b/2 trial of Nana-val in advanced EBV+ solid tumors expected in 2023 Received orphan drug designation (ODD) from the European Commission for Nana-val for the treatment of diffuse large B-cell lymphoma; sixth ODD globally and the second in Europe Cash, cash equivalents and investments of $91.0 million as of December 31, 2022; anticipated cash runway into late 2024 SAN DIEGO, March 13, 2023 (GLOBE NEWSWIRE) — Viracta...

Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

MENLO PARK, Calif., March 13, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the fourth quarter and year ended December 31, 2022 and issued financial guidance for the year ending December 31, 2023. Recent Financial Highlights Generated 2022 total revenue of $71.3 million, an increase of 46% compared to 2021 Generated fourth quarter 2022 total revenue of $20.5 million, an increase of 40% compared to the prior year period Reduced fourth quarter 2022 operating expenses by $3.7 million versus the third quarter of 2022 Improved total gross margin to 83% in 2022 versus 82% in 2021 Recent Business Highlights The number of...

T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument placements in 2022 LEXINGTON, Mass., March 13, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the fourth quarter and full year ended December 31, 2022. Recent Commercial and Financial Highlights Achieved full year 2022 total revenue of $22.3 million, including product revenue of $11.3 million and research contribution revenue of $11.0 million. Achieved record full year 2022 sepsis and related product revenue of $8.4 million, representing growth of 17% compared to 2021, and record fourth quarter sepsis test revenue in the U.S. Achieved record full year 2022 sepsis-driven T2Dx® Instrument placements,...

Ocean Power Technologies, Inc. Announces Third Quarter Fiscal 2023 Results

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

Results include Third Quarter Revenue Growth of 51.7% MONROE TOWNSHIP, N.J., March 13, 2023 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (“OPT” or “the Company”) (NYSE American: OPTT), today announced financial results for its fiscal third quarter ended January 31, 2023 (“Q323”), including year-to-date revenue growth of over 74.7% and total order growth of 111%. Highlights from the third quarter and recent activity include: Total orders for the Q323 were $0.8 million, as compared to $0.7 million for the third quarter ended January 31, 2022 (“Q322”). Total orders for the nine months ended Q323 increased 111% to $3.8 million, from total orders of $1.8 million for the same period in the prior year. Revenues for the Q323 were $0.7 million, reflecting a growth of 51.7% over Q322 revenues. Revenues of $1.8...

Day: March 13, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice